Montvale, NJNCT07359859Now EnrollingIRB Ready

Hematologic Malignancies Clinical Trial in Montvale, NJ

Access cutting-edge hematologic malignancies treatment through this clinical trial at a research site in Montvale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Montvale location

Preparing your pre-screening questions…

Expert Care in Montvale

Access hematologic malignancies specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematologic malignancies treatment provided free

Apply for This Montvale Location

Check if you qualify for this hematologic malignancies clinical trial in Montvale, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Montvale

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Montvale site if eligible
  4. 4Begin participation

About This Hematologic Malignancies Study in Montvale

The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic hematopoietic stem cell transplantation (allo-HCT).

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Patients ≥18- years-old at time of consent
Diagnosis: hematologic malignancy in morphologic remission (blasts \<5%, no evidence of extramedullary disease in AML or MDS). Patients with CR with incomplete count recovery (CRp or CRi) or minimal residual disease are allowed. Patients with lymphoma must have a complete or partial response
Donor: related or unrelated 7-8/8 HLA-matched or related haploidentical
Karnofsky score ≥ 70%
Female subjects of childbearing potential (\<50 years old) have a negative serum or urine pregnancy test. Females of childbearing potential are defined as females without prior hysterectomy or who have had any evidence of menses in the past 12 months. °Sexually active females of childbearing potential enrolled in the study must agree to consistently use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of the study drug. Effective birth control includes: \*Intrauterine device (IUD) plus one barrier method \*Stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method \*2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm); or \
A vasectomized partner.
For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria

Recipient of CD34+ selected or engineered stem cell graft
Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin)
Patients with an active secondary malignancy or prior malignancy requiring systemic therapy within the past 5 years. Exceptions include adequately treated localized non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma), as well as localized prostate cancer considered low risk and stable under treatment or surveillance.
Severely impaired renal function defined by serum creatinine \> 2mg/dL, renal dialysis requirement.
Use of investigational agent within 14 days pre-HCT
Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Uncontrolled psychiatric illness
Female patient who is pregnant or breastfeeding
Known allergy or sensitivity to ruxolitinib

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Montvale?

Yes, this clinical trial (NCT07359859) has an active research site in Montvale, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematologic Malignancies Treatment Options in Montvale, NJ

If you're searching for hematologic malignancies treatment options in Montvale, NJ, this clinical trial (NCT07359859) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Montvale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematologic malignancies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematologic malignancies clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Montvale, NJ

See all interstitial cystitis clinical trials recruiting in Montvale — not just this study.

Browse Interstitial Cystitis Trials in Montvale →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Montvale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Montvale, NJ